

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE

	States Patent and Trademark Office
Address:	COMMISSIONER FOR PATENTS
	P.O. Box 1450
	Alexandria, Virginia 22313-1450
	www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/633,523	08/05/2003	Takeshi Okada	03500.015395.1	5405
5514	7590 12/15/2006		EXAM	INER
	CK CELLA HARPER	OLSEN, ALLAN W		
30 ROCKEFELLER PLAZA NEW YORK, NY 10112			ART UNIT	PAPER NUMBER
new road, wr rone			1763	
			DATE MAILED: 12/15/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. Applicant(s) Advisory Action 10/633.523 OKADA ET AL. Before the Filing of an Appeal Brief **Art Unit** Examiner 1763 Allan Olsen --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 22 November 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. Make The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) \square The period for reply expires $\underline{3}$ months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL ___. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of 2. The Notice of Appeal was filed on ____ filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. Mean The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below): (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal: and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See attachment. (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): _ 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. 🛛 For purposes of appeal, the proposed amendment(s): a) 🖾 will not be entered, or b) 🗌 will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1,2,4-7,9 and 11. Claim(s) withdrawn from consideration: _____ AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be

Allan Claen

entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a

showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:

13. ☐ Other: .

REQUEST FOR RECONSIDERATION/OTHER

Allan Olsen Primary Examiner Art Unit: 1763

Notice of Non-Compliant Amendment (37 CFR 1.121)

Application No.	Applicant(s)	Applicant(s)		
10/633,523	OKADA ET AL.			
Examiner	Art Unit			
Allan Olsen	1763			

The MAILING DATE of this communication appears on the cover sneet with the correspondence address	
The amendment document filed on <u>22 November 2006</u> is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121 or 1.4. In order for the amendment document to be compliant, correction of the following item(s) is required.	
THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT: 1. Amendments to the specification: A. Amended paragraph(s) do not include markings. B. New paragraph(s) should not be underlined. C. Other	
 2. Abstract: A. Not presented on a separate sheet. 37 CFR 1.72. B. Other 	
 3. Amendments to the drawings: A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d). B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required. C. Other 	
 ✓ 4. Amendments to the claims: ☐ A. A complete listing of all of the claims is not present. ☐ B. The listing of claims does not include the text of all pending claims (including withdrawn claims) ☐ C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended). ☐ D. The claims of this amendment paper have not been presented in ascending numerical order. ☑ E. Other: Claim 1 fails to show the strike-through of all text that has been deleted. 	
☐ 5. Other (e.g., the amendment is unsigned or not signed in accordance with 37 CFR 1.4):	
For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714.	J
TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:	
1. Applicant is given no new time period if the non-compliant amendment is an after-final amendment or an amendment filed after allowance. If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the entire corrected amendment must be resubmitted.	en
2. Applicant is given one month, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the correction, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to Quayle action. If any of above boxes 1, to 4, are checked, the correction required is only the corrected section of non-compliant amendment in compliance with 37 CFR 1.121. Extensions of time are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action.	ent a
Failure to timely respond to this notice will result in: Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendme filed in response to a Quayle action; or Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.	nt
Legal Instruments Examiner (LIE), if applicable Telephone No.	
U.S. Patent and Trademark Office PTOL-324 (01-06) Part of Paper No. 200612 Notice of Non-Compliant Amendment (37 CFR 1.121)	13

Application/Control Number: 10/633,523

Art Unit: 1763

Attachment to Advisory Action

AMENDMENTS

3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because

(a) They raise new issues that would require further consideration and/or search.

(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal.

Regarding Advisory action item 3(a), as repeated above, claim 1 was amended to include the limitations of claims 2, 4, 5 and 7. While claims 2, 4, 5 and 7 have previously been considered, the combination of all limitations from each of these claims has not previously been presented or considered.

Regarding item 3(c), see the following response to arguments.

Response to Arguments

Applicant's arguments filed November 22, 2006 have been fully considered but they are not persuasive.

Applicant argues that claim 1 requires, in part, carrying out feature (b), which is:

"(b) performing a plasma treatment by irradiating the substrate subjected to the dry etching process with plasma in an atmosphere formed by introducing a mixture of a halogen gas as claimed and 0_2 gas wherein the amount of 0_2 gas is not greater than 30%"

Applicant asserts that:

"Seki, et al.'s 4th embodiment (Fig. 9 and [0178]) does not state that the claimed dry etching process is performed prior to the use of CF_4/O_2 , and therefore such constitutes neither a description nor a suggestion of feature (b). In this regard, Applicants respectfully submit that Seki, et al.'s Fig. 9 shows that when a gas mixture is used at the optimum ratio, the effect of plasma treatment using fluorine gas is suppressed and the contact angle of polyimide is reduced"

Application/Control Number: 10/633,523

Art Unit: 1763

With regard to the assertion that Seki does not state that the claimed dry etching process is performed prior to the use of CF₄/O₂, the examiner again notes paragraph [0055] of Seki which states (with emphasis added):

"This invention provides a surface modification method which comprises a first process for performing an oxygen plasma treatment on the substrate whereon the banks are formed, and a second process for performing, consecutively, a fluorine-based gas plasma treatment."

Regarding figure 9 of Seki, the examiner does not understand how applicant arrived at their conclusion. Figure 9 shows that Seki's optimum CF₄: O₂ ratio correlates closely to applicant's claim limitation that requires forming a plasma from a mixture of a halogen gas and O₂, wherein the amount of O₂ gas is not greater than 30%. Contrary to that which was argued by applicant, figure 9 shows that the contact angle with respect to polyimide, increases with the fluorine treatment.




FIG.9